Short answer
Altimmune, Inc. (ALT) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 fiscal 2026 results for quarter ended June 30, 2026.
Altimmune, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the detailed financial results
- Results announcement dated August 12, 2026
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $22.8M, or $0.12 per share, versus $22.1M and $0.27 in Q2 2025
- Cash, cash equivalents and investments $519M at June 30, 2026, supporting continued clinical development
- PERFORMA Phase 3 MASH trial initiated, with 52-week data anticipated in 2029
- RECLAIM Phase 2 AUD trial met primary and key secondary endpoints in 100 patients, strengthening regulatory prospects
- RESTORE Phase 2 ALD enrollment completed, with topline data expected in the second half of 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Altimmune, Inc. 8-K filings
Get the next ALT 8-K as it lands
Follow ALT for push alerts, or ask the research agent what this filing means.